AXL and lung adenocarcinoma: Indeed, pharmacologic Axl inhibition using a selective Axl inhibitor, bemcentinib or BGB324, in lung adenocarcinoma cell lines (PC9 and H1975) significantly decreased PD-L1 and PD-L2, another ligand that binds to PD-1 [79].